Lung cancer: Difficult to diagnose, difficult to treat, easy to prevent | Asian Tribune.

AceProbe – DiagnaAce Lung Panels-offers the first ever validated test validated on Indian population.

An improved understanding of the molecular pathways that drive malignancy in non-small cell lung cancer (NSCLC) has led to the development of agents (DUGS) that specifically target differences between normal and malignant cell.

The most useful biomarkers for predicting the efficacy of targeted therapy in advanced NSCLC are somatic genome alterations known as “driver mutations.” These mutations occur in the genome of cancer cells within genes that encoding for proteins critical to cell growth and survival. Driver mutations often impart an oncogene-addicted biology to the transformed cell, meaning that the mutated protein engenders reliance within the cancer cell to receive a signal from the driver in order to survive.

The best characterized of these biomarkers are EGFR mutations and ALK translocation. Identification of these biomarkers has led to highly specific treatments that have resulted in a major advance in therapy for tumors harboring these abnormalities.

Lung cancer: Difficult to diagnose, difficult to treat, easy to prevent | Asian Tribune.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s